Sharemaestro Newsreel

Zhonghong Medical Reports H1 2026 Net Profit Surge of Over 26-Fold

Zhonghong Pulin Medical Products Co., Ltd. XIAMEN, China, Sept. 21, 2026 (GLOBE NEWSWIRE) -- Zhonghong Pulin Medical Products Co., Ltd. ("Zhonghong Medical", 300981.SZ) recently disclosed its interim report for 2026. According to the report, the company achieved a revenue of RMB 1.478 billion in …

Shanghai Pharmaceuticals Holding Co Ltd's Dividend Analysis

This article first appeared on GuruFocus. A Closer Look at the Upcoming Payout and Long-Term Dividend Profile Shanghai Pharmaceuticals Holding Co Ltd (SHPMY) recently announced a total dividend of $0.07 per share, with the ex-dividend date set for 2026-09-17. This amount consists of a …

Mindray North America Advances Respiratory Care with the Launch of the SV70 Non-Invasive Ventilator

Following the Philips V60 withdrawal, the SV70 offers respiratory departments a proven path forward built on clinical confidence and long-term standardization. MAHWAH, N.J., Sept. 15, 2026 /PRNewswire/ -- Mindray, a global leader in healthcare innovation across perioperative, medical imaging, and critical care, today announced …

Jim Cramer Calls Kailera Therapeutics (KLRA) “The Most Speculative Stock On Earth”

During the lightning round of the September 10 episode of Mad Money, a caller asked if Kailera Therapeutics, Inc. (NASDAQ:KLRA) is a buy, sell, or hold. In response, Jim Cramer said: Okay, I actually know this, but okay, here's the problem. Let's say I …

Big Pharma Is Pouring Billions Into China’s Biotechs

Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China. Continue Reading

InnoCare Announces Approval of Clinical Trial of Novel Bispecific ADC ICP-B381 Targeting PSMA/ STEAP1 in China

InnoCare Pharma BEIJING, Sept. 08, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 9969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) …

AirNexis Therapeutics Announces that AN01, a Dual PDE3/4 Inhibitor Dry Powder Inhaler (DPI) Met its Primary Endpoint in a Phase 2b COPD Study (HSK39004-T1-202) Conducted in China by AirNexis' partner Haisco Pharmaceutical Group

AirNexis Therapeutics, Inc. Phase 2b dose ranging data presented at ERS show both doses of AN01 delivered significant and clinically relevant improvements in lung function versus placebo at Week 4 Trial comprised of broad COPD population, including participants on background single or dual bronchodilator …

Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion

SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to HK$1 billion. The shares …

The Bull Case For BeOne Medicines (ONC) Could Change Following US-Backed HER2 Regimen And Onshoring Deal

BeOne Medicines recently secured U.S. FDA approvals for TEVIMBRA and ZIIHERA-based regimens in first-line HER2-positive gastroesophageal cancers and entered a voluntary agreement with the U.S. government to expand access to its oncology drugs while investing more than US$1.00 billion in U.S. manufacturing. This combination …

BeOne (ONC) Secured a Pharmaceutical-Tariff Exemption After More than $1B of U.S. Manufacturing Investment. Are the Pricing Concessions Worth It?

BeOne Medicines AG (NASDAQ:ONC) entered a voluntary agreement with the U.S. government that combines pharmaceutical-tariff protection with commitments on manufacturing, Medicaid participation, and the pricing of future medicines. The agreement gives BeOne Medicines AG (NASDAQ:ONC) an exemption from Section 232 pharmaceutical tariffs while recognizing …

BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference

SAN CARLOS, Calif., September 01, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will participate in the Morgan Stanley Annual Global Healthcare Conference on September 14, 2026, with a fireside chat at 11:30 a.m. EDT. …

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing SAN CARLOS, Calif., August 31, 2026--(BUSINESS WIRE)--BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand …

BeOne Medicines Announces New Phase 3 Survival Data Reinforcing Benefit of ZIIHERA-Containing Regimens in First-Line HER2+ Gastroesophageal Cancer

Findings provide further evidence of overall survival benefit of TEVIMBRA plus ZIIHERA and chemotherapy regimen in HER2+ GEA ZIIHERA plus chemotherapy demonstrated statistically significant overall survival benefit at second interim analysis of HERIZON-GEA-01 trial SAN CARLOS, Calif., August 31, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: …

WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion

SHANGHAI, Aug. 30, 2026 /PRNewswire/ -- WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim dividend of RMB 1.03 billion in …

LBX Pharmacy Chain Joint Stock Company（上交所：603883）第二季度业绩刚刚出炉：以下是分析师对该公司今年的预测

Tigermed Announces 2026 Interim Results

HANGZHOU, China, Aug. 28, 2026 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. (300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its 2026 interim results (the "Reporting Period"). This document is for information …

BeOne Medicines Ltd. - Sponsored ADR (ONC) is a Great Momentum Stock: Should You Buy?

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the "long context," investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of …

Wuxi Apptec Co Ltd. - Sponsored ADR (WUXAY) Is a Great Choice for 'Trend' Investors, Here's Why

Most of us have heard the dictum "the trend is your friend." And this is undeniably the key to success when it comes to short-term investing or trading. But it isn't easy to ensure the sustainability of a trend and profit from it. Often, …

Junshi Biosciences Announces 2026 Interim Financial Results and Provides Corporate Updates

Junshi Biosciences SHANGHAI, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences," HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced its 2026 interim financial results and provided corporate …

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status Regimen poised to become standard of care in this difficult-to-treat disease. SAN CARLOS, Calif., August …

BeOne Medicines Ltd. - Sponsored ADR (ONC) Now Trades Above Golden Cross: Time to Buy?

BeOne Medicines Ltd. - Sponsored ADR (ONC) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ONC's 50-day simple moving average broke out above its 200-day moving average; this is known as a "golden cross." …

Fosun Pharma Announces 2026 Interim Results

Globalization Accelerates Value Realization of Innovative Drugs SHANGHAI, Aug. 25, 2026 /PRNewswire/ -- On August 25, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its interim results for 2026. In the first half of 2026 ("the Reporting Period", or 1H2026), the Company recorded …

InnoCare Reports 2026 Interim Results, Sustained Profitability and Key Milestones Achieved

InnoCare Pharma BEIJING, Aug. 24, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer and autoimmune diseases, today announced the interim results and business highlights for the six months ended 30 June 2026. InnoCare delivered robust …

Imeik Technology Development Co.,Ltd.（深交所：300896）刚刚错失盈利预期：以下是分析师对接下来走势的看法

APT Medical Inc. 超越了分析师预期：看看共识预测今年的情况如何

Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum

SHANGHAI, Aug. 19, 2026 /PRNewswire/ -- Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first half of 2026. During the reporting period, innovative drugs remained the Company's key growth driver, while globalization initiatives continued to validate the global value …

盈利超预期：Jiangsu Nhwa Pharmaceutical Co., LTD刚刚超出分析师预测，分析师们一直在更新他们的模型。

BeOne Medicines, BeOne Care Foundation, and The Max Foundation Renew Partnership to Expand Access to BRUKINSA® for the Treatment of Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries

Renewed collaboration builds on access provided to more than 300 patients with CLL to date and plans to support approximately 1,000 patients through 2028 SAN CARLOS, Calif. & SEATTLE, August 18, 2026--(BUSINESS WIRE)--BeOne Medicines Ltd. ("BeOne") (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global …

Is BeOne Medicines AG (ONC) Deal With Revolution Medicines (RVMD) a Win-Win for Both Companies?

Two oncology powerhouses, BeOne Medicines AG (NASDAQ:ONC) and Revolution Medicines, Inc. (NASDAQ:RVMD), announced a major multi-part clinical collaboration and regional licensing deal. Under the August 10 agreement, the companies will combine select clinical-stage assets from BeOne with Revolution's four clinical-stage RAS(ON) inhibitors to evaluate …

Judge blocks US decision to add WuXi to list of firms tied to Chinese military

By David Shepardson and Alexandra Alper WASHINGTON, Aug 7 (Reuters) - A federal judge on Friday barred the U.S. Defense Department from including Chinese biotechnology company WuXi AppTec Co ‌on a list of companies believed to support Beijing's military, saying the government lacked ‌evidence …

INTCO Medical Recognized in S&P Global Sustainability Yearbook (China Edition) 2025 for ESG Progress

ZIBO, China, Aug. 5, 2026 /PRNewswire/ -- INTCO Medical ("the Company"), a leading global manufacturer of disposable gloves, has been included in S&P Global's Sustainability Yearbook (China Edition) 2025 and recognized as an Industry Mover for its ESG progress, reflecting the Company's continued progress …

AsymBio Secures US$184 Million Capital Injection to Support Long-Term Growth

SHANGHAI, Aug. 4, 2026 /PRNewswire/ -- AsymBio, a biologics-focused Contract Development and Manufacturing Organization (CDMO) and a subsidiary of Asymchem Group (stock codes: 002821.SZ / 6821.HK), today announced a total capital injection of RMB 1.2397 billion (approximately US$184 million) into AsymBio by Asymchem Group, …

ADLM announces 2026 Top Corporate Supporter Award recipients and thanks them for their essential backing

ANAHEIM, Calif., July 28, 2026 /PRNewswire/ -- The Association for Diagnostics & Laboratory Medicine (ADLM) is pleased to announce the recipients of its 2026 Top Corporate Supporter Award, a distinction given to companies and organizations that generously support the association through advertising, sponsorships, and …